JP2010270125A - 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 - Google Patents
機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 Download PDFInfo
- Publication number
- JP2010270125A JP2010270125A JP2010151403A JP2010151403A JP2010270125A JP 2010270125 A JP2010270125 A JP 2010270125A JP 2010151403 A JP2010151403 A JP 2010151403A JP 2010151403 A JP2010151403 A JP 2010151403A JP 2010270125 A JP2010270125 A JP 2010270125A
- Authority
- JP
- Japan
- Prior art keywords
- glp
- irritable bowel
- bowel syndrome
- pharmaceutical composition
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
【解決手段】消化管において抗分泌作用および平滑筋弛緩特性を有するグルカゴン様ペプチド−1(GLP−1)およびその誘導体からなるクラスから選択される消化管ペプチドホルモンを機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物。また、GLP−1およびその誘導体からなる上記クラスから選択される少なくとも1つと1つ以上の他の消化管ペプチドホルモンまたはその誘導体とを組み合わせて、薬理学的に許容される添加剤とともに含有する医薬組成物、ならびに、GLP−1およびその誘導体からなる上記クラスの少なくとも1つの有効量を投与することによって、機能性消化不良もしくは過敏性腸症候群またはその両方を治療する方法。
【選択図】なし
Description
Claims (7)
- 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物を製造するための、消化管において抗分泌作用および平滑筋弛緩特性を有するグルカゴン様ペプチド−1(GLP−1)ならびにその誘導体からなるクラスから選択される消化管ペプチドホルモンの使用。
- 前記医薬組成物において、前記GLP−1またはその誘導体が1つ以上の他の消化管ペプチドホルモンまたは誘導体と組み合わせられている、請求項1記載の使用。
- 前記医薬組成物において、ソマトスタチンがGLP−1と組み合わせられている、請求項2記載の使用。
- 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物であって、消化管において抗分泌作用および平滑筋弛緩特性を有するGLP−1ならびにその誘導体からなる群から選択される少なくとも1つと、そのような作用および特性を有する1つ以上の他の消化管ペプチドホルモンならびにその誘導体との組み合わせを、薬理学的に許容される添加剤とともに含有することを特徴とする医薬組成物。
- GLP−1と併せてソマトスタチンを含有することを特徴とする、請求項4記載の医薬組成物。
- 機能性消化不良もしくは過敏性腸症候群またはその両方に罹患しているヒト患者において、機能性消化不良もしくは過敏性腸症候群またはその両方を治療する方法であって、消化管において抗分泌作用および平滑筋弛緩特性を有するGLP−1ならびにその誘導体からなる群の少なくとも1つの有効量を該患者に投与することを含む方法。
- ソマトスタチンと併せてGLP−1を投与する、請求項6記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802080A SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000553128A Division JP2002517468A (ja) | 1998-06-11 | 1999-06-08 | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010270125A true JP2010270125A (ja) | 2010-12-02 |
Family
ID=20411665
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000553128A Ceased JP2002517468A (ja) | 1998-06-11 | 1999-06-08 | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 |
JP2010151403A Pending JP2010270125A (ja) | 1998-06-11 | 2010-07-01 | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000553128A Ceased JP2002517468A (ja) | 1998-06-11 | 1999-06-08 | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6348447B1 (ja) |
EP (2) | EP1405642A1 (ja) |
JP (2) | JP2002517468A (ja) |
AT (1) | ATE252912T1 (ja) |
AU (1) | AU738994B2 (ja) |
CA (1) | CA2321700C (ja) |
CZ (1) | CZ300873B6 (ja) |
DE (1) | DE69912434T2 (ja) |
DK (1) | DK1094834T3 (ja) |
ES (1) | ES2205845T3 (ja) |
HU (1) | HUP0103147A3 (ja) |
NO (1) | NO327738B1 (ja) |
NZ (1) | NZ506163A (ja) |
PL (1) | PL198802B1 (ja) |
PT (1) | PT1094834E (ja) |
RU (1) | RU2226402C2 (ja) |
SE (1) | SE9802080D0 (ja) |
WO (1) | WO1999064060A1 (ja) |
ZA (1) | ZA200004080B (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
DK2280020T3 (en) | 1999-06-29 | 2016-05-02 | Mannkind Corp | Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
WO2001068112A2 (en) * | 2000-03-14 | 2001-09-20 | Goeke Burkhard | Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
AU6323001A (en) * | 2000-05-19 | 2001-12-03 | Bionebraska Inc | Treatment of acute coronary syndrome with glp-1 |
PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
MXPA04008068A (es) | 2002-02-20 | 2004-11-26 | Lilly Co Eli | Metodo para administrar moleculas de glp-1. |
ES2300568T3 (es) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | Aparato de inhalacion. |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
ES2338789T3 (es) | 2003-06-18 | 2010-05-12 | Tranzyme Pharma Inc. | Antagonistas macrociclicos del receptor de motilina. |
US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
CA2575692C (en) | 2004-08-20 | 2014-10-14 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
BR122019022692B1 (pt) | 2004-08-23 | 2023-01-10 | Mannkind Corporation | Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo |
JP2008536881A (ja) * | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Glp−1分子と制吐剤との医薬製剤 |
PT1881850E (pt) | 2005-05-13 | 2010-11-26 | Lilly Co Eli | Compostos peguilados de glp-1 |
CA2617859A1 (en) | 2005-06-30 | 2007-01-11 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Glp-1 pharmaceutical compositions |
JP4994374B2 (ja) * | 2005-07-29 | 2012-08-08 | ジオファーム オンコロジー, インコーポレイテッド | がんを治療するための化合物および方法 |
HUE028691T2 (en) | 2005-09-14 | 2016-12-28 | Mannkind Corp | A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients |
EP1986679B1 (en) | 2006-02-22 | 2017-10-25 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
GEP20125659B (en) * | 2006-12-29 | 2012-10-10 | Ipsen Pharma Sas | Pharmaceutical compositions containing glucagon-like peptide-1 (glp-1) |
WO2008134425A1 (en) * | 2007-04-27 | 2008-11-06 | Cedars-Sinai Medical Center | Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders |
AU2008316636B2 (en) * | 2007-10-24 | 2014-02-06 | Mannkind Corporation | Delivery of active agents |
JP2011500850A (ja) * | 2007-10-24 | 2011-01-06 | マンカインド コーポレイション | Glp−1による副作用を防止する方法 |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
AR072114A1 (es) | 2008-06-13 | 2010-08-04 | Mannkind Corp | Un inhalador de polvo seco y sistema para suministro de farmacos |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
CA2727147A1 (en) | 2008-06-17 | 2009-12-23 | Otsuka Chemical Co., Ltd. | Glycosylated glp-1 peptide |
BRPI0914308B8 (pt) | 2008-06-20 | 2021-06-22 | Mannkind Corp | sistema de inalação |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US8614185B2 (en) | 2009-05-04 | 2013-12-24 | Centocor Ortho Biotech Inc. | Fusion proteins of alpha-MSH derivatives and Fc |
JP5751641B2 (ja) | 2009-05-06 | 2015-07-22 | ヤンセン バイオテツク,インコーポレーテツド | メラノコルチン受容体結合コンジュゲート |
KR101875969B1 (ko) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
TWI471138B (zh) * | 2009-07-29 | 2015-02-01 | Daiichi Sankyo Co Ltd | 賦予經黏膜吸收性之類似腸動素的胜肽化合物 |
EP2495255A4 (en) | 2009-10-30 | 2013-05-15 | Otsuka Chemical Co Ltd | GLYCOSYLATED FORM OF AN ANTIGENIC GLP-1 ANALOG |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
EP2555791B1 (en) | 2010-04-09 | 2017-11-01 | Sinai Health System | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
US9089538B2 (en) | 2010-04-27 | 2015-07-28 | Zealand Pharma A/S | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use |
RU2571331C1 (ru) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
BR112012033295A2 (pt) | 2010-07-02 | 2016-10-11 | Angiochem Inc | polipeptídeos curtos e contendo d-aminoácido para conjugados terapêuticos e seu uso |
PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
JP6133270B2 (ja) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | 薬剤カートリッジのためのブリスター包装 |
CN103619175B (zh) | 2011-04-12 | 2016-08-17 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
JP6018640B2 (ja) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム |
JP6359972B2 (ja) | 2011-11-03 | 2018-07-18 | ジーランド ファーマ アクティーゼルスカブ | Glp−1受容体アゴニストペプチドガストリンコンジュゲート |
TR201903918T4 (tr) | 2012-03-22 | 2019-04-22 | Novo Nordisk As | Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması. |
JP6356660B2 (ja) | 2012-03-22 | 2018-07-11 | ノヴォ ノルディスク アー/エス | 送達剤を含む組成物およびその調製 |
HRP20231060T1 (hr) | 2012-03-22 | 2023-12-22 | Novo Nordisk A/S | Pripravci peptida glp-1 i njihova priprava |
CN104487056A (zh) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S(股份有限公司) | 包含肽和递送剂的片剂制剂 |
SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
CN104662038B (zh) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
WO2014144895A1 (en) | 2013-03-15 | 2014-09-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
AU2014290438B2 (en) | 2013-07-18 | 2019-11-07 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
KR102569036B1 (ko) | 2013-10-17 | 2023-08-23 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
RU2716985C2 (ru) | 2014-10-29 | 2020-03-17 | Зилэнд Фарма А/С | Соединения-агонисты gip и способы |
KR101825048B1 (ko) | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
KR102568272B1 (ko) | 2015-02-11 | 2023-08-21 | 지맥스 바이오팜 엘엘씨 | Glp-1r 항체 융합 단백질의 안정한 약제학적 용액 제형 |
RU2735762C2 (ru) | 2015-04-16 | 2020-11-06 | Зилэнд Фарма А/С | Ацилированный аналог глюкагона, его применение и способы получения |
AU2017371516C1 (en) | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
CN110305211A (zh) | 2018-03-20 | 2019-10-08 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
US5994500A (en) * | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
-
1998
- 1998-06-11 SE SE9802080A patent/SE9802080D0/xx unknown
-
1999
- 1999-06-08 CZ CZ20004491A patent/CZ300873B6/cs not_active IP Right Cessation
- 1999-06-08 ES ES99930089T patent/ES2205845T3/es not_active Expired - Lifetime
- 1999-06-08 DE DE69912434T patent/DE69912434T2/de not_active Expired - Lifetime
- 1999-06-08 PL PL343104A patent/PL198802B1/pl not_active IP Right Cessation
- 1999-06-08 WO PCT/SE1999/000997 patent/WO1999064060A1/en active IP Right Grant
- 1999-06-08 NZ NZ506163A patent/NZ506163A/en unknown
- 1999-06-08 HU HU0103147A patent/HUP0103147A3/hu unknown
- 1999-06-08 AU AU46697/99A patent/AU738994B2/en not_active Ceased
- 1999-06-08 AT AT99930089T patent/ATE252912T1/de not_active IP Right Cessation
- 1999-06-08 US US09/445,571 patent/US6348447B1/en not_active Expired - Lifetime
- 1999-06-08 JP JP2000553128A patent/JP2002517468A/ja not_active Ceased
- 1999-06-08 PT PT99930089T patent/PT1094834E/pt unknown
- 1999-06-08 EP EP20030024624 patent/EP1405642A1/en not_active Withdrawn
- 1999-06-08 DK DK99930089T patent/DK1094834T3/da active
- 1999-06-08 RU RU2000133249/14A patent/RU2226402C2/ru not_active IP Right Cessation
- 1999-06-08 EP EP99930089A patent/EP1094834B1/en not_active Expired - Lifetime
- 1999-06-08 CA CA2321700A patent/CA2321700C/en not_active Expired - Fee Related
-
2000
- 2000-08-10 ZA ZA200004080A patent/ZA200004080B/xx unknown
- 2000-12-06 NO NO20006194A patent/NO327738B1/no not_active IP Right Cessation
-
2010
- 2010-07-01 JP JP2010151403A patent/JP2010270125A/ja active Pending
Non-Patent Citations (5)
Title |
---|
JPN6009037628; Regulatory Peptides Vol.74,No.1, 199804, p19-25 * |
JPN6009037629; Journal of Pharmacology and Experimental Therapeut Vol.268,No.3, 1994, p1206-1211 * |
JPN6012039589; Scandinavian Journal of Gastroenterology. Suppleme Vol.116, 1985, p1-48 * |
JPN6012039591; Scandinavian Journal of Gastroenterology Vol.20,No.10, 1985, p1163-1168 * |
JPN6012039594; Therapeutic Research Vol.7,No.6, 1987, p1215-1226 * |
Also Published As
Publication number | Publication date |
---|---|
PT1094834E (pt) | 2004-03-31 |
ATE252912T1 (de) | 2003-11-15 |
JP2002517468A (ja) | 2002-06-18 |
AU4669799A (en) | 1999-12-30 |
CZ300873B6 (cs) | 2009-09-02 |
ES2205845T3 (es) | 2004-05-01 |
CA2321700A1 (en) | 1999-12-16 |
DE69912434T2 (de) | 2004-05-06 |
EP1094834A1 (en) | 2001-05-02 |
PL198802B1 (pl) | 2008-07-31 |
CA2321700C (en) | 2011-05-03 |
NO20006194L (no) | 2001-01-25 |
NZ506163A (en) | 2004-10-29 |
ZA200004080B (en) | 2001-12-24 |
CZ20004491A3 (en) | 2001-05-16 |
DE69912434D1 (de) | 2003-12-04 |
NO327738B1 (no) | 2009-09-14 |
EP1094834B1 (en) | 2003-10-29 |
EP1405642A1 (en) | 2004-04-07 |
SE9802080D0 (sv) | 1998-06-11 |
HUP0103147A2 (hu) | 2002-01-28 |
DK1094834T3 (da) | 2004-01-05 |
WO1999064060A1 (en) | 1999-12-16 |
PL343104A1 (en) | 2001-07-30 |
US6348447B1 (en) | 2002-02-19 |
NO20006194D0 (no) | 2000-12-06 |
HUP0103147A3 (en) | 2002-02-28 |
RU2226402C2 (ru) | 2004-04-10 |
AU738994B2 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010270125A (ja) | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 | |
Wiseman et al. | Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders | |
Grosman et al. | Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide. | |
Scarpignato et al. | Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility | |
RU2432167C2 (ru) | Способ уменьшения симптомов изжоги и гастроэзофагиальной рефлюксной болезни (гэрб) с помощью особых полисахаридов | |
RU2000133249A (ru) | Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней | |
KR20010041211A (ko) | 안지오텐신 ιι 타입 2 수용체 효능제를 포함하는 제약제제 및 그의 용도 | |
Van der Sijp et al. | Circulating gastrointestinal hormone abnormalities in patients with severe idiopathic constipation | |
Walt et al. | Comparison of twice-daily ranitidine with standard cimetidine treatment of duodenal ulcer. | |
Corsetti et al. | Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation | |
Robertson et al. | Cisapride in the treatment of gastro‐oesophageal reflux disease | |
GB2244918A (en) | Pharmaceutical compositions comprising somatosatin and cholanic acid derivatives | |
Scarpignato | The place of octreotide in the medical management of the dumping syndrome | |
M’Koma et al. | Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones | |
Ahlman et al. | Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. | |
Holt et al. | Peptic ulcer disease: Physiology and pathophysiology | |
JP2013040206A (ja) | 消化器系の運動をイパモレリンを用いて刺激する方法 | |
KR102289089B1 (ko) | 인후두 역류질환 치료 또는 예방용 조성물 | |
RU2147884C1 (ru) | Способ лечения язвенной болезни желудка и двенадцатиперстной кишки | |
Sugiyama et al. | Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring | |
EP4146221A1 (en) | Treatment of hyperuricemia | |
JP2001501224A (ja) | 胸焼けを予防及び治療するための方法及び組成物 | |
Shiratori et al. | Inhibitory Effect of Intraduodenal Administration of Somatostatin Analogue SDZ CO 61 1 on Rat Pancreatic Exocrine Secretion | |
RU2106877C1 (ru) | Способ лечения идиопатического дерматомиозита | |
JPH06107564A (ja) | ガストリン拮抗剤の新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121031 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130108 |